In recent years, infection with the Human Papilloma Virus (HPV) has emerged as a major cause of oropharynx cancer including cancer of the tonsils and base of tongue. In fact, according to the Centers for Disease Control, more than 70 percent of the oropharyngeal cancer diagnosed in the United States is now linked to HPV with the percentage expected to continue to climb. Oropharyngeal tumors driven by HPV have an improved prognosis compared with cancers not associated with HPV. At Weill Cornell, we have significant experience and expertise in the diagnosis and management of HPV related oropharyngeal cancer. We practice a patient centered approach which benefits from the ability to offer multiple treatment modalities including transoral robotic surgery (TORS), transoral laser surgery (TLM), as well as state of the art radiation and chemotherapy. We are also actively researching the ability to de-escalate therapy to maintain high cure rates while reducing the toxicity and side-effects of treatment.